Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Sickle Cell Disease

Part of Anemia

9 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Sickle Cell Disease

116 trials tracked for Sickle Cell Disease: 15 in phase 3 or 4 and 5 with published results. The most-cited published study has 606 citations.

116Trials tracked

15Phase 3 & 4

0Recruiting

5With published results

Phase distribution

Phase 4 5 Phase 3 10 Phase 2 49 Phase 1 15 Other / NA 37

Phase 3 Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE) Completed · 606 cited
Phase 3 Novel Use Of Hydroxyurea in an African Region With Malaria Completed · 150 cited
Phase 4 Pilot Study for Patients With Poor Response to Deferasirox Completed · 91 cited
Phase 3 Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial Completed · 11 cited
Phase 3 Age of Blood in Sickle Cell Transfusion Completed · 1 cited
Phase 4 Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease Completed

Show 44 more trials

Phase 4 Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions Completed
Phase 4 Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Completed
Phase 4 Actigraphy Improvement With Voxelotor (ActIVe) Study Completed
Phase 3 Stem Cell Transplant for Hemoglobinopathy Completed
Phase 3 Stem Cell Transplantation for Sickle Cell Anemia Completed
Phase 3 A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Completed
Phase 3 Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis Completed
Phase 3 Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally Completed
Phase 3 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed
Phase 2 Pharmacokinetics of Oral Hydroxyurea Solution Completed
Phase 2 Hydroxyurea and EPO in Sickle Cell Disease Completed
Phase 2 Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs Completed
Phase 2 Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension Completed
Phase 2 Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease Completed
Phase 2 A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) Completed
Phase 2 Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease Completed
Phase 2 Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease Completed
Phase 2 An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001 Completed
Phase 2 SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial) Completed
Phase 2 Simvastatin (Zocor) Therapy in Sickle Cell Disease Completed
Phase 2 High Dose Vitamin D for Sickle Cell Disease Completed
Phase 2 A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases Completed
Phase 2 A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease Completed
Phase 2 A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease Completed
Phase 2 Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease Completed
Phase 2 Daily Vitamin D for Sickle-cell Respiratory Complications Completed
Phase 2 Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies Completed
Phase 2 Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises Completed
Phase 2 Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo Completed
Phase 2 Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients Completed
Phase 2 Nitrous Oxide Analgesia Vaso-occlusive Crisis Completed
Phase 2 Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease Completed
Phase 2 Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease Completed
Phase 2 Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease Completed
Phase 2 Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow Completed
Phase 2 HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity Completed
Phase 2 Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Completed
Phase 2 Vitamin D for Sickle-cell Respiratory Complications Completed
Phase 2 A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease Completed
Phase 2 Arginine Therapy for Sickle Cell Disease Pain Completed
Phase 2 Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO). Completed
Phase 2 Decitabine for High-Risk Sickle Cell Disease Completed
Phase 2 Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease Completed
Phase 2 Assessing the Safety of Buprenorphine in People With Sickle Cell Disease Completed

Showing the 50 most-cited and recently-updated of 116 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Research across Anemia

Related studies from across the Anemia family.

Systematic review finds first FDA-approved CRISPR therapy and broader clinical trial exploration

Genetics & Precision Medicine Sys. Review

Systematic review finds first FDA-approved CRISPR therapy and broader clinical trial exploration First CRISPR gene therapy approved for blood disorders, with broader research underway

A systematic review of clinical trials registered at clinicaltrials.gov found the first CRISPR-Cas9 therapy obtained FDA approval in late 20…

The first CRISPR gene therapy is approved for sickle-cell anemia and β-thalassemia, with ongoing trials exploring its use for cancer and inf…

Frontiers Apr 3, 2026

Report examines use of recommended health care measures for sickle cell anemia complications in youth

Report examines use of recommended health care measures for sickle cell anemia complications in youth Report examines use of preventive care for children with sickle cell anemia

A report describes the use of recommended health care measures to prevent complications of sickle cell anemia in children and adolescents in…

A new report looked at how children and adolescents with sickle cell anemia in the U.S.

CDC Apr 2, 2026

Questions about Sickle Cell Disease

Did the Renizgamglogene autotemcel infusion increase hemoglobin in severe Sickle Cell Disease patients?

Yes, the Renizgamglogene autotemcel infusion increased hemoglobin in severe Sickle Cell Disease patients, with most treated individuals showing engraftment and higher hemoglobin levels within the first year of follow-up.

Full answer →

What echocardiographic profiles are seen in adults with Sickle Cell Disease?

Adults with sickle cell disease show three main echocardiographic profiles: high cardiac output with enlarged chambers, mild remodeling with higher pulmonary pressure, or near-normal structure; these patterns predict different clinical outcomes.

Full answer →